[1] Fridman WH,Miller I,Sautès-Fridman C,et al.Therapeutic targeting of the colorectal tumor stroma[J].Gastroenterology,2020,158(2):303-321.DOI:10.1053/j.gastro.2019.09.045.
[2] Chen Y,Zhang S,Wang Q,et al.Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein[J].J Hematol Oncol,2017,10(1):36.DOI:10.1186/s13045-017-0408-0.
[3] Yang L,Zhang Y.Tumor-associated macrophages: from basic research to clinical application[J].J Hematol Oncol,2017,10(1):58.DOI:10.1186/s13045-017-0430-2.
[4] Yang L,Dong Y,Li Y,et al.IL-10 derived from M2 macrophage promotes cancer stemness via JAK1/STAT1/NF-κB/Notch1 pathway in non-small cell lung cancer[J].Int J Cancer,2019,145(4):1099-1110.DOI:10.1002/ijc.32151.
[5] Zhang J,Yan Y,Yang Y,et al.High infiltration of tumor-associated macrophages influences poor prognosis in human gastric cancer patients, associates with the phenomenon of EMT[J].Medicine (Baltimore),2016,95(6):e2636.DOI:10.1097/MD.0000000000002636.
[6] Nielsen SR,Schmid MC.Macrophages as key drivers of cancer progression and metastasis[J].Mediators Inflamm,2017,2017(1):9624760.DOI:10.1155/2017/9624760.
[7] Guo Q,Jin Z,Yuan Y,et al.New mechanisms of tumor-associated macrophages on promoting tumor progression: recent research advances and potential targets for tumor immunotherapy[J].J Immunol Res,2016,2016(4):9720912.DOI:10.1155/2016/9720912.
[8] Wang B,Li Q,Qin L,et al.Transition of tumor-associated macrophages from MHC class Ⅱ(hi) to MHC class Ⅱ(low) mediates tumor progression in mice[J].BMC Immunol,2011,12:43.DOI:10.1186/1471-2172-12-43.
[9] Ferrer-Admetlla A,Sikora M,Laayouni H,et al.A natural history of FUT2 polymorphism in humans[J].Mol Biol Evol,2009,26(9):1993-2003.DOI:10.1093/molbev/msp108.
[10] Badawi MA,Abouelfadl DM,El-Sharkawy SL,et al.Tumor-associated macrophage (TAM) and angiogenesis in human colon carcinoma[J].Open Access Maced J Med Sci,2015,3(2):209-214.DOI:10.3889/oamjms.2015.044.
[11] Lee J,Song J,Kwon ES,et al.CTHRC1 promotes angiogenesis by recruiting Tie2-expressing monocytes to pancreatic tumors[J].Exp Mol Med,2016,48(9):e261.DOI:10.1038/emm.2016.87.
[12] Wang X,Zhu Q,Lin Y,et al.Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer[J].Br J Cancer,2017,117(9):1371-1382.DOI:10.1038/bjc.2017.297.
[13] Argyle D,Kitamura T.Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors[J].Front Immunol,2018,9:2629.DOI:10.3389/fimmu.2018.02629.
[14] Boimel PJ,Smirnova T,Zhou ZN,et al.Contribution of CXCL12 secretion to invasion of breast cancer cells[J].Breast Cancer Res,2012,14(1):R23.DOI:10.1186/bcr3108.
[15] Ries CH,Cannarile MA,Hoves S,et al.Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy[J].Cancer Cell,2014,25(6):846-859.DOI:10.1016/j.ccr.2014.05.016.
[16] Pyonteck SM,Akkari L,Schuhmacher AJ,et al.CSF-1R inhibition alters macrophage polarization and blocks glioma progression[J].Nat Med,2013,19(10):1264-1272.DOI:10.1038/nm.3337.
[17] DeNardo DG,Brennan DJ,Rexhepaj E,et al.Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy[J].Cancer Discov,2011,1(1):54-67.DOI:10.1158/2159-8274.CD-10-0028.
[18] Strachan DC,Ruffell B,Oei Y,et al.CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells[J].Oncoimmunology,2013,2(12):e26968.DOI:10.4161/onci.26968.
[19] Xu J,Escamilla J,Mok S,et al.CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer[J].Cancer Res,2013,73(9):2782-2794.DOI:10.1158/0008-5472.CAN-12-3981.
[20] Li X,Yao W,Yuan Y,et al.Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma[J].Gut,2017,66(1):157-167.DOI:10.1136/gutjnl-2015-310514.
[21] Vidyarthi A,Khan N,Agnihotri T,et al.TLR-3 stimulation skews M2 macrophages to M1 through IFN-αβ signaling and restricts tumor progression[J].Front Immunol,2018,9:1650.DOI:10.3389/fimmu.2018.01650.
[22] Liu L,He H,Liang R,et al.ROS-inducing micelles sensitize tumor-associated macrophages to TLR3 stimulation for potent immunotherapy[J].Biomacromolecules,2018,19(6):2146-2155.DOI:10.1021/acs.biomac.8b00239.
[23] Ramesh A,Kumar S,Nandi D,et al.CSF1R- and SHP2-inhibitor-loaded nanoparticles enhance cytotoxic activity and phagocytosis in tumor-associated macrophages[J].Adv Mater,2019,31(51):e1904364.DOI:10.1002/adma.201904364.
[24] Locatelli SL,Careddu G,Serio S,et al.Targeting cancer cells and tumor microenvironment in preclinical and clinical models of hodgkin lymphoma using the dual PI3Kδ/γ inhibitor RP6530[J].Clin Cancer Res,2019,25(3):1098-1112.DOI:10.1158/1078-0432.CCR-18-1133.
[25] Choi J,Kim HY,Ju EJ,et al.Use of macrophages to deliver therapeutic and imaging contrast agents to tumors[J].Biomaterials,2012,33(16):4195-4203.DOI:10.1016/j.biomaterials.2012.02.022.
[26] Zanganeh S,Hutter G,Spitler R,et al.Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues[J].Nat Nanotechnol,2016,11(11):986-994.DOI:10.1038/nnano.2016.168.
[27] Song M,Liu T,Shi C,et al.Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia[J].ACS Nano,2016,10(1):633-647.DOI:10.1021/acsnano.5b06779.
|